drugset / Trial / NCT03750071
VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery
Timeline
- Start
- 2018-11-21
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | VXM01 | Vaccine | — | — |